Recce Pharmaceuticals

Recce Pharmaceuticals Debt

The Debt of Recce Pharmaceuticals (RCE.AX) as of Nov 10, 2026 is 10.44 M AUD. In the previous year, Debt was 10.77 M AUD — a change of -3.04% (lower).

Debt

10.44 MAUD

YoY

-3.04%

Last updated:

In 2026, Recce Pharmaceuticals's total debt was 10.44 M AUD, a -3.04% change from the 10.77 M AUD total debt recorded in the previous year.

The Recce Pharmaceuticals Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
737,408.00 AUD
Jan 1, 2020
83,235.00 AUD
Jan 1, 2021
126,949.00 AUD
Jan 1, 2022
74,762.00 AUD
Jan 1, 2023
250,568.00 AUD
Jan 1, 2024
811,190.00 AUD
Jan 1, 2025
10.77 M AUD
Jan 1, 2026
10.44 M AUD
The Recce Pharmaceuticals Debt history
YEARDebtYoY
10.44 MAUD-3.04%
10.77 MAUD+1,227.46%
811,190.00AUD+223.74%
250,568.00AUD+235.15%
74,762.00AUD-41.11%
126,949.00AUD+52.52%
83,235.00AUD-88.71%
737,408.00AUD+25,692.51%
2,859.00AUD-99.11%
322,579.00AUD+4,522.80%
6,978.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Recce Pharmaceuticals Stock analysis

What does Recce Pharmaceuticals do? Recce Pharmaceuticals Ltd. develops pharmaceutical drugs targeting germ-killing therapies, focusing on anti-infective solutions. The company’s pipeline includes RECCE 327, an intravenous and topical therapy for serious bacterial infections including superbugs, RECCE 435 as an oral treatment for bacterial infections, and RECCE 529 for viral infections. All compounds are 100% water soluble across all pH levels in liquid form, leveraging multi-layered mechanisms to combat bacterial and viral mutations. The company operates through research and development, with no additional product lines or services mentioned. Recce Pharmaceuticals Ltd. generates revenue primarily through the development and potential commercialization of its anti-infective drugs. The target market includes healthcare providers and institutions treating serious infections, particularly those dealing with antibiotic-resistant bacteria and viral pathogens. The company’s focus on broad-spectrum synthetic polymer anti-infectives positions it for partnerships with pharmaceutical distributors and healthcare systems seeking novel treatments for life-threatening infections. The business model relies on the progression of its drug pipeline from research to clinical trials and eventual market entry. RECCE 327, RECCE 435, and RECCE 529 are the only products described, with no mention of licensing agreements, partnerships, or additional revenue streams beyond drug development and sales. The company’s financial success depends on the successful advancement of these compounds through regulatory approval processes. Recce Pharmaceuticals is one of the most popular companies on Eulerpool.

Debt Details

Understanding Recce Pharmaceuticals's Debt Structure

Recce Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Recce Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Recce Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Recce Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Recce Pharmaceuticals stock

Debt of Recce Pharmaceuticals is 10.44 M AUD in 2026.

Debt of Recce Pharmaceuticals changed from 10.77 M AUD to 10.44 M AUD, representing a -3.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Recce Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Recce Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Recce Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Recce Pharmaceuticals